Indeed, Rivera and Colbert wrote that “the long-term use of SYK inhibitors should be closely monitored and its use might be inappropriate for people with a family history of breast cancer” [77], whereas Khan and coworkers asked whether “oral spleen tyrosine kinase inhibitors could lead to neoplastic transformation” [78]. Here, SYK is linked to breast carcinoma.